Nektar Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing immunomodulatory agents for autoimmune diseases and cancer. The company's primary pipeline candidate, rezpegaldesleukin, is a resolution therapeutic designed to stimulate regulatory T cells to restore immune homeostasis in conditions such as atopic dermatitis and alopecia areata. Nektar also develops NKTR-0165/0166 for autoimmune disorders and NKTR-255 for oncology. The company previously partnered with Eli Lilly for the development and commercialization of rezpegaldesleukin, a collaboration that was terminated in 2023, allowing Nektar to regain full rights to the asset. Nektar collaborates with TrialNet to evaluate rezpegaldesleukin in patients with type 1 diabetes. The company applies its expertise in immunology to advance drug candidates through preclinical and clinical development stages.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage nektar.com
Sector Healthcare IR page ir.nektar.com
Tags
immunotherapy, autoimmune diseases, atopic dermatitis, alopecia areata, oncology, regulatory t cells, clinical-stage, drug discovery, rezpegaldesleukin, NKTR-0165, NKTR-0166, NKTR-255, TrialNet, Eli Lilly
Press page —

Metrics

Valuation  
Market cap $ 2.071B
Market cap (USD) $ 2.071B
P/E -9.66
PEG —
P/BV 2.44
P/S 39.69
P/OCF -8.06
P/FCF -8.04
Dividend yield —
Turnover / mcap —
Returns  
ROE -217.9%
ROI -117.2%
ROIC -75.1%
Profit margin -297.1%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock —
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 30
Quality score -76.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 55.232M 98.427M 90.122M 92.055M 101.907M 152.915M 114.617M 1.193B 307.711M 165.436M 230.784M 200.707M 148.921M 81.191M 71.48M 159.039M 71.931M 90.185M 273.027M 217.718M 126.279M 114.27M 106.257M 94.845M 77.468M —
Net profit -164.076M -118.961M -276.056M -368.198M -523.837M -444.44M -440.667M 681.313M -96.692M -153.524M -81.177M -53.916M -162.013M -171.855M -133.978M -37.938M -102.519M -34.336M -32.761M -154.761M -185.111M -101.886M -46.682M -107.468M -250.008M -97.403M
Free cash flow -208.682M -177.177M -193.471M -309.683M -427.649M -320.545M -354.966M 703.975M -90.09M -123.416M -84.278M -151.982M -42.618M -140.339M -123.464M -87.328M 23.349M -164.637M 113.506M -115.239M -95.953M -102.383M -94.947M -91.302M -85.095M -89.592M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 42.28 0.93 0.57 2.26 13.51 17 21.59 32.87 59.72 12.27 16.85 15.5 11.35 7.41 5.59 13.95 5.57 4.37 12.23 14.65 — — — — — —
Price performance 12m 44.46 0.65 -0.75 -0.83 -0.21 -0.21 -0.34 -0.45 3.87 -0.27 0.09 0.37 0.53 0.33 -0.6 1.5 0.27 -0.64 -0.17 — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 15.7M 5.01M 43.2M 36.8M 38.9M 22.5M 5.98M 1.21M 0.00 —
↳ YoY growth -21.4% -68.0% +761.8% -14.8% +5.7% -42.2% -73.4% -79.9% -100.0%
↳ 5y CAGR +26.0% -2.9% +80.9% +59.1% +14.3% +7.5% +3.6% -51.1%
Lease liabilities (USD) — — 96.2M 155M 150M 143M 131M 118M 103M 85.8M
Cash and deposits (USD) 59.6M 4.76M 195M 96.4M 199M 25.2M 88.2M 35.3M 44.3M 15.1M
Right-of-use assets (USD) — — 83.5M 134M 126M 117M 53.4M 18M 8.41M 2.94M
Cash flow detail
Operating cash flow (USD) -117M -80.4M 718M -329M -313M -413M -304M -193M -176M -209M
Purchases of property, plant and equipment (USD) -6.39M -9.68M -14.2M -26.3M -7.26M -15M -5.68M -865,000 -1.47M -171,000
Change in receivables (cash effect) (USD) 4.27M 10.7M -25.5M 6.41M 1.91M 12.4M 16.5M 4.78M -3.05M 0.00
Change in inventories (cash effect) (USD) 237,000 383,000 -655,000 -1.28M -2.63M -509,000 -3.4M 699,000 497,000 0.00
Change in payables (cash effect) (USD) 518,000 2.07M 971,000 13M 2.38M -11.7M 3.1M -2.88M 2.67M -625,000
Share buybacks (cash effect) (USD) — — — — — — — 0.00 -3M 0.00
Interest paid (cash effect) (USD) -20.6M -20.1M -19.5M -19.2M -9.74M 0.00 0.00 — — —
Income taxes paid (cash effect) (USD) -757,000 -556,000 -618,000 -555,000 -539,000 -325,000 -272,000 -2.66M -76,000 195,000
Share-based compensation (USD) 25.9M 36.6M 88.1M 99.8M 94.3M 94.7M 57.3M 33.4M 21.6M 12.6M
Operating cash flow before change in receivables (USD) -121M -91.1M 744M -335M -315M -425M -321M -197M -173M -209M
Free cash flow (OCF - PPE - intangibles) (USD) -123M -90.1M 704M -355M -321M -428M -310M -193M -177M -209M
Income detail
Research and development expense (USD) 204M 268M 400M 435M 409M 400M 218M 114M 121M 117M
↳ 5y CAGR +10.0% +12.5% +16.0% +24.1% +17.5% +14.5% -4.1% -22.2% -22.6% -22.1%
Total comprehensive income (USD) -154M -96.4M 677M -435M -446M -526M -371M -269M -119M -164M
Comprehensive income to owners (USD) -154M -96.4M 677M -435M -446M -526M -371M -269M -119M -164M
Provision for credit losses (USD) — — — — — — — 0.00 0.00 0.00
Credit cost ratio (credit losses / average receivables) (%) — — — — — — — 0.0% 0.0% —
Reported Mar 1, 2017 Mar 1, 2018 May 9, 2019 Feb 28, 2020 Feb 26, 2021 Mar 1, 2022 Feb 28, 2023 Mar 14, 2025 Mar 14, 2025 Mar 13, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Nektar Therapeutics — Regulation FD Bull 0 Bear 0 Routine

In conjunction with its third quarter financial results announced yesterday, November 12, 2026, Nektar Therapeutics (the “Company”) reported $952.9 million in cash and investments in marketable securities as of September 30, 2026. Consistent with its prior guidance, the Company expects that this cash balance will extend its cash runway into the third quarter of 2028 past the initial data readouts from the Phase 3 ZENITH AD trials in atopic dermatitis in the summer of 2028.

Forward-Looking Statements

The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions, and uncertainties.

SAN FRANCISCO, November 12, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced its financial results for the third quarter ended September 30, 2026, and provided a business update.

Cash and investments in marketable securities on September 30, 2026, were $952.9 million as compared to $245.8 million on December 31, 2025.

“This was a pivotal quarter for Nektar as we moved rezpegaldesleukin quickly into Phase 3 development,” said Howard Robin, President and Chief Executive Officer of Nektar. “We have now initiated all three global ZENITH AD registrational trials in atopic dermatitis and our global ZENITH AA registrational trial in alopecia areata is on track to begin in December, earlier than previously planned. The strong body of clinical and translational data generated to-date for rezpegaldesleukin reinforce our conviction in its novel and differentiated Treg mechanism, which targets multiple inflammatory pathways that underpin chronic autoimmune disease.

Skip to content

investor relations hero

Release details

SAN FRANCISCO, Oct. 27, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter ended September 30, 2026 on Thursday, November 12, 2026, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.

Nektar Logo

This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: https://ir.nektar.com/. The web broadcast of the conference call will be available for replay through December 12, 2026.

To access the conference call, please pre-register here. All registrants will receive dial-in information and a PIN allowing them to access the live call.

About Nektar Therapeutics

Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in atopic dermatitis, alopecia areata, and Type 1 diabetes mellitus. Nektar's pipeline also includes preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422.

Nektar is headquartered in San Francisco, California. For further information, visit www.nektar.com and follow us on LinkedIn.

Prompts

Nektar Therapeutics (ticker NKTR), listed in United States.

Company History

Date Change Detail
Jan 23, 2003 Renamed INHALE THERAPEUTIC SYSTEMS INC → NEKTAR THERAPEUTICS

ETFs Holding Nektar Therapeutics

ETF Weight in ETF Shares Market value As of
LFSC 2.97% 52,589 $ 3.754M Aug 31, 2026
SPIT 2.10% 9,974 $ 711.944K Aug 31, 2026
RUSC 0.13% 1,450 $ 101.225K Jun 30, 2026
RESM 0.11% 56 $ 3,909.36 Jun 30, 2026
VFMO 0.05% 12,679 $ 905.027K Aug 31, 2026
AVSC 0.02% 17,836 $ 649.944K Nov 16, 2026
FTLS short -0.02% -13,025 $ 0.00 Nov 16, 2026
MSSM 0.01% 1,219 $ 87.012K Aug 31, 2026
AVUS 0.00% 1,811 $ 65.993K Nov 16, 2026